Drug Trial Radar · NCT06732323
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
504
Planned (sponsor's estimate)
Start
Sep 4, 2025
Primary completion
Jun 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
Conditions
- Triple-Negative Breast Cancer (TNBC)
Interventions
ESG401Drug
IV infusion on day 1,8, and 15 of each 28 day cycle
Investigator's Choice ChemotherapyDrug
Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)Time frame: Randomization up to approximately 28 months
- Overall Survival (OS)Time frame: Randomization up to approximately 41 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.